Streetbeat News

Analyst Ratings

IONQ

IonQ, Inc. (NYSE:IONQ) shares are trading higher with above-average volume, adding to strong gains for the week. This surge comes after Needham analyst Quinn Bolton maintained a Buy rating and raised the price target from $9 to $11. Bolton expressed confidence in IonQ's QC technology and its ability to deliver on its roadmap, citing a transaction with QuantumBasel as evidence. IonQ shares are up more than 45% over the last week.

Portfolio Pulse from Ryan Gustafson

June 28, 2023 | 7:21 pm

ODFL

A significant bearish stance has been taken on Old Dominion Freight Line (NASDAQ:ODFL) by a large investor, as observed from the options history. The overall sentiment of these big-money traders is 80% bearish and 20% bullish. The whales have been targeting a price range from $310.0 to $380.0 for ODFL over the last 3 months. The current price of ODFL is up 2.84% at $369.46. Analysts have mixed opinions with Stephens & Co. and B of A Securities being bullish while Susquehanna and Jefferies are neutral to bearish.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:16 pm

TDWRF

Scotiabank analyst Robert Hope has maintained an 'Outperform' rating on Tidewater Renewables (OTC:TDWRF), but lowered the price target from C$16 to C$15.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2023 | 7:05 pm

OXY

Benzinga's options scanner detected over 22 options trades for Occidental Petroleum (NYSE:OXY) totaling $765,001. Whales have been targeting a price range from $20.0 to $82.5 for Occidental Petroleum over the last 3 months. The price of OXY is up 1.02% at $57.71. Truist Securities and Piper Sandler have maintained their Buy and Neutral ratings on Occidental Petroleum, respectively.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:03 pm

GOLD

A whale investor has taken a bullish stance on Barrick Gold (NYSE:GOLD), with 66% of investors opening trades with bullish expectations and 33% with bearish. The whale has been targeting a price range from $10.0 to $22.0 for Barrick Gold over the last 3 months. The price of GOLD is currently down -0.66% at $16.55. The next earnings are expected to be released in 40 days.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:03 pm

GS

Goldman Sachs Gr (NYSE:GS) has received various analyst ratings in the last quarter, with 2 bullish, 9 somewhat bullish, and 6 indifferent. The average 12-month price target for the company is $395.94, a 3.7% decrease from the previous average of $411.17.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:01 pm

BETRF

PHRRF

BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application for non-hallucinogenic LSD derivatives, including its 2-bromo-LSD derivative BETR-001, which is expected to begin clinical trials for Major Depressive Disorder. The patent covers the composition, treatment uses, and a novel production method. The company's CEO, Dr. Ahmad Doroudian, highlighted the compound's neuroplasticity properties and efficacy in preclinical models of depression, anxiety, and pain. Another biotech company, PharmaTher Holdings (OTC:PHRRF), recently fast-tracked an application for its proprietary racemic ketamine, KETARX, for the treatment of levodopa-induced dyskinesia in Parkinson’s disease.

Portfolio Pulse from Lara Goldstein

June 28, 2023 | 7:01 pm

SNX

TD Synnex (NYSE:SNX) has received various analyst ratings in the last quarter, with 3 bullish, 2 somewhat bullish, and 3 indifferent. The average 12-month price target for the company, according to 8 analysts, is $108.38, a decrease of 7.93% from the previous average of $117.71.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:01 pm

ZI

14 analysts have provided ratings for ZoomInfo Technologies (NASDAQ:ZI) in the last quarter, with 6 being bullish, 7 somewhat bullish, and 1 indifferent. The average price target is $31.57, implying an upside from the current price of $25.565. This represents a 7.88% decrease from the previous average price target of $34.27.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:01 pm

FHTX

Foghorn Therapeutics (NASDAQ:FHTX) has received positive analyst ratings in the last quarter, with 6 bullish and 3 somewhat bullish ratings. The average 12-month price target for the company is $18.0, a 10.0% decrease from the previous average price target of $20.00.

Portfolio Pulse from Benzinga Insights

June 28, 2023 | 7:01 pm